Cargando…

Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination

Everolimus (EVE) provides an alternative to maintenance immunosuppression when conventional immunosuppression cannot be tolerated. EVE can be utilized with a calcineurin inhibitor (CNI) minimization or elimination strategy. To date, clinical studies investigating EVE after lung transplant (LTx) have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ivulich, Steven, Paul, Eldho, Kirkpatrick, Carl, Dooley, Michael, Snell, Greg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Health Archive
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894878/ https://www.ncbi.nlm.nih.gov/pubmed/36744051 http://dx.doi.org/10.3389/ti.2023.10704

Ejemplares similares

Rescue Everolimus Post Lung Transplantation is Not Associated With an Increased Incidence of CLAD or CLAD-Related Mortality
por: Ivulich, Steven, et al.
Publicado: (2023)

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

Enhancing Beta Cell Replacement Therapies: Exploring Calcineurin Inhibitor-Sparing Immunosuppressive Regimens
por: Caldara, Rossana, et al.
Publicado: (2023)

Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients
por: Bergh, Niklas, et al.
Publicado: (2020)

Three-Year Outcomes in Kidney Transplant Recipients Switched From Calcineurin Inhibitor-Based Regimens to Belatacept as a Rescue Therapy
por: Morel, Antoine, et al.
Publicado: (2022)

Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients
por: Pacheco, Larissa Sgaria, et al.
Publicado: (2018)

Calcineurin inhibitor toxicity in a renal transplant recipient
por: Charney, Douglas A., et al.
Publicado: (2009)

Calcineurin-Inhibitor Minimization in Liver Transplant Patients with Calcineurin-Inhibitor-Related Renal Dysfunction: A Meta-Analysis
por: Kong, Yuan, et al.
Publicado: (2011)

The effect of calcineurin inhibitors on anthropometric measurements in kidney transplant recipients
por: Sayilar, Emel Isiktas, et al.
Publicado: (2022)

Immunosuppression with Calcineurin Inhibitor after Renal Transplant Failure Inhibits Allosensitization
por: López del Moral Cuesta, Covadonga, et al.
Publicado: (2020)

Evidence for the Immunosuppressive Potential of Calcineurin Inhibitor-Sparing Regimens in Liver Transplant Recipients with Impaired Renal Function
por: Ide, Kentaro, et al.
Publicado: (2011)

Impact of Calcineurin Inhibitor-Based Immunosuppression Maintenance During the Dialysis Period After Kidney Transplant Failure on the Next Kidney Graft Outcome: A Retrospective Multicenter Study With Propensity Score Analysis
por: Noelle, Juliette, et al.
Publicado: (2023)

The Cyclophilin-Dependent Calcineurin Inhibitor Voclosporin Inhibits SARS-CoV-2 Replication in Cell Culture
por: Ogando, Natacha S., et al.
Publicado: (2022)

mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis
por: Xie, Xishao, et al.
Publicado: (2015)

Effect of gene polymorphisms on the levels of calcineurin inhibitors in Indian renal transplant recipients
por: Ashavaid, T., et al.
Publicado: (2010)

Calcineurin inhibitors differentially alter the circadian rhythm of T-cell functionality in transplant recipients
por: Leyking, Sarah, et al.
Publicado: (2015)

Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients
por: Tawhari, Ibrahim, et al.
Publicado: (2022)

A Multi-Modal Approach to Islet and Pancreas Transplantation With Calcineurin-Sparing Immunosuppression Maintains Long-Term Insulin Independence in Patients With Type I Diabetes
por: Wisel, Steven A., et al.
Publicado: (2023)

The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial
por: Van Keer, Jan, et al.
Publicado: (2017)

Everolimus and Early Calcineurin Inhibitor Withdrawal: 3-Year Results From a Randomized Trial in Liver Transplantation
por: Sterneck, M, et al.
Publicado: (2014)

Long-term results of a calcineurin inhibitor-free immunosuppression based on Thymoglobulin® and mycophenolate mofetil in elderly kidney transplant recipients
por: Kamar, Nassim, et al.
Publicado: (2008)

Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients
por: Hasbal, Nuri Baris, et al.
Publicado: (2021)

Calcineurin Inhibitors and COVID-19
por: Hage, René, et al.
Publicado: (2022)

Calcineurin Inhibitors in Membranous Nephropathy
por: Ponticelli, Claudio, et al.
Publicado: (2021)

Calcineurin Inhibitors and COVID-19
por: Hage, René, et al.
Publicado: (2022)

Renal impairment after liver transplantation - a pilot trial of calcineurin inhibitor-free vs. calcineurin inhibitor sparing immunosuppression in patients with mildly impaired renal function after liver transplantation
por: Gerhardt, T, et al.
Publicado: (2009)

The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial
por: Sommerer, Claudia, et al.
Publicado: (2014)

Everolimus‐facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2‐year results from the subgroup analysis of the TRANSFORM study
por: Watarai, Yoshihiko, et al.
Publicado: (2021)

A comparison of mycophenolate mofetil and calcineurin inhibitor as maintenance immunosuppression for kidney transplant recipients: A meta-analysis of randomized controlled trials
por: DENG, Jin, et al.
Publicado: (2021)

A systematic review and meta-analysis comparing everolimus and calcineurin inhibitors (CNIs) to mycophenolate and CNIs in kidney transplant patients
por: Vergara-Rejante, Larraine, et al.
Publicado: (2023)

A polypeptide inhibitor of calcineurin blocks the calcineurin-NFAT signalling pathway in vivo and in vitro
por: Wang, Ping, et al.
Publicado: (2021)

Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis
por: Rafael-Vidal, Carlos, et al.
Publicado: (2021)

Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation
por: Leal, Rita, et al.
Publicado: (2017)

Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants
por: Kumar, Dhiren, et al.
Publicado: (2017)

Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study
por: Saliba, Faouzi, et al.
Publicado: (2022)

Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors
por: Yu, Ji Hyun, et al.
Publicado: (2016)

An Integrated Transcriptomic Approach to Identify Molecular Markers of Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients
por: Rhone, Erika T., et al.
Publicado: (2021)

Potential interactions between uraemic toxins and drugs: an application in kidney transplant recipients treated with calcineurin inhibitors
por: André, Camille, et al.
Publicado: (2021)

Calcineurin regulation of cytoskeleton organization: a new paradigm to analyse the effects of calcineurin inhibitors on the kidney
por: Descazeaud, Virginie, et al.
Publicado: (2012)

Impact of Sirolimus versus Mycophenolate Mofetil on Kidney Function after Calcineurin Inhibitor Dose Reduction in Liver Transplant Recipients
por: Chiang, Heng-Yi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ua7lo7n08e8co54e1iv4dqjfmq